
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ADO-5030
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Recipient : Adial Pharmaceuticals
Deal Size : $83.0 million
Deal Type : Agreement
Adial Pharma gets Milestone Payment from Adovate After Phase 1 Study Start
Details : Under the agreement, the ADO-5030 compound is being developed by Adovate as a potential first-line therapy for asthma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $0.4 million
May 13, 2025
Lead Product(s) : ADO-5030
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Recipient : Adial Pharmaceuticals
Deal Size : $83.0 million
Deal Type : Agreement
